[go: up one dir, main page]

PE20040763A1 - Derivados de aminoalcoxiindoles como ligandos de los receptores 5-ht6 - Google Patents

Derivados de aminoalcoxiindoles como ligandos de los receptores 5-ht6

Info

Publication number
PE20040763A1
PE20040763A1 PE2003001211A PE2003001211A PE20040763A1 PE 20040763 A1 PE20040763 A1 PE 20040763A1 PE 2003001211 A PE2003001211 A PE 2003001211A PE 2003001211 A PE2003001211 A PE 2003001211A PE 20040763 A1 PE20040763 A1 PE 20040763A1
Authority
PE
Peru
Prior art keywords
disease
alkyl
indol
pyrrolidin
heterocyclic ring
Prior art date
Application number
PE2003001211A
Other languages
English (en)
Inventor
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32469485&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20040763(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20040763A1 publication Critical patent/PE20040763A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE AMINOALCOXIINDOLES DE FORMULA I, DONDE m ES 0 A 3; n ES 0 A 2; CADA R1 ES H, HALO, ALQUILO, HALOALQUILO, HIDROXILO, HETEROALQUILO, NITRO, ALCOXILO, CIANO, NRaRb, ENTRE OTROS; Ra y Rb SON H O ALQUILO, O DOS R1 FORMAN UN ALQUILENO O ALQUILENDIOXILO; R2 ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDO; R3 ES H O ALQUILO; p ES 2 O 3; R5, R6, R7 Y R8 SON H O ALQUILO; O UNO DE R5 Y R6 JUNTO CON UNO DE R7 Y R8 Y LOS ATOMOS ENTRE LOS MISMO FORMAN UN ANILLO HETEROCICLICO DE 4-7 MIEMBROS; O BIEN R7 Y R8 JUNTO CON EL NITROGENO FORMAN UN ANILLO HETEROCICLICO DE 5-7 MIEMBROS; O UNO DE R7 Y R8 JUNTO CON R3 Y LOS ATOMOS ENTRE LOS MISMOS FORMAN UN ANILLO HETEROCICLICO DE 5-7 MIEMBROS. SON COMPUESTOS PREFERIDOS: 3-FENILSULFANIL-7-(2-PIRROLIDIN-1-IL-ETOXI)-1H-INDOL, 3-BENCENOSULFONIL-7-(2-PIRROLIDIN-1-IL-ETOXI)-1H-INDOL, 3-(3-CLORO-BENCENOSULFONIL)-7-(2-PIRROLIDIN-1-IL-ETOXI)-1H-INDOL, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE ELABORACION Y A UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE. ESTOS COMPUESTO SON MODULADORES DE LA 5-HIDROXITRIPTAMINA (5-HT) Y PARTICULARMENTE ACTUAN COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR 5-HT6 Y SON UTILES PARA EL TRATAMIENTO O PREVENCION DE UN ESTADO DE ENFERMEDAD DEL SISTEMA NERVIOSO CENTRAL COMO PSICOSIS, ESQUIZOFRENIA, DEPRESION MANIACA, TRASTORNO DEL DEFICIT DE ATENCION, ENFERMEDAD DE PARKINSON, ESCLEROSIS AMIOTROFICA LATERAL, ENFERMEDAD DE ALZHEIMER Y ENFERMEDAD DE HUNTINGTON
PE2003001211A 2002-12-03 2003-11-28 Derivados de aminoalcoxiindoles como ligandos de los receptores 5-ht6 PE20040763A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43050602P 2002-12-03 2002-12-03

Publications (1)

Publication Number Publication Date
PE20040763A1 true PE20040763A1 (es) 2004-11-20

Family

ID=32469485

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001211A PE20040763A1 (es) 2002-12-03 2003-11-28 Derivados de aminoalcoxiindoles como ligandos de los receptores 5-ht6

Country Status (24)

Country Link
US (1) US7084169B2 (es)
EP (1) EP1569638B1 (es)
JP (1) JP4339795B2 (es)
KR (1) KR100755580B1 (es)
CN (1) CN1713908B (es)
AR (1) AR042155A1 (es)
AT (1) ATE372113T1 (es)
AU (1) AU2003289903B2 (es)
BR (1) BR0316962A (es)
CA (1) CA2508315A1 (es)
DE (1) DE60316180T2 (es)
ES (1) ES2291722T3 (es)
HR (1) HRP20050457A2 (es)
MX (1) MXPA05005790A (es)
MY (1) MY138466A (es)
NO (1) NO20052730L (es)
NZ (1) NZ539950A (es)
PA (1) PA8589801A1 (es)
PE (1) PE20040763A1 (es)
PL (1) PL377464A1 (es)
RU (1) RU2350602C2 (es)
TW (1) TWI284124B (es)
WO (1) WO2004050085A1 (es)
ZA (1) ZA200504412B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5417142A (en) * 1992-12-18 1995-05-23 Caterpillar Inc. Hydraulic amplifier
AR039127A1 (es) 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
MXPA06000795A (es) 2003-07-22 2006-08-23 Arena Pharm Inc Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo.
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
US20090221644A1 (en) * 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
JP5146766B2 (ja) * 2005-08-15 2013-02-20 ワイス・エルエルシー ５−ヒドロキシトリプタミン−６リガンドとしての置換−３−スルホニルインダゾール誘導体
CN101370775A (zh) * 2006-01-13 2009-02-18 惠氏公司 作为5-羟基色胺受体配体的经磺酰基取代1h-吲哚
CA2647141A1 (en) * 2006-04-12 2007-10-25 Wyeth Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
WO2008113818A1 (en) * 2007-03-21 2008-09-25 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
CN102558020B (zh) * 2011-12-12 2013-09-18 温州大学 一种3-芳巯基吲哚类化合物的合成方法
CN103288707B (zh) * 2013-05-28 2015-12-23 浙江大学 一种3-苯巯基吲哚衍生物的制备方法
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
MX388281B (es) 2015-06-12 2025-03-11 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamiento de un trastorno conductual del sueño rem.
HK1247555A1 (zh) 2015-07-15 2018-09-28 Axovant Sciences Gmbh 用於预防和治疗与神经变性疾病相关的幻觉的作为5-ht2a血清素受体的调节剂的二芳基脲和芳基杂芳基脲衍生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1139760A (en) * 1979-03-07 1983-01-18 Makiko Sakai 1,4-dioxaspiro¬4,5| decene compounds
FR2589863B1 (fr) * 1985-11-12 1988-07-29 Sanofi Sa Derives d'hydroxy-4 indole, leur procede de preparation et leur utilisation
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
US4939138A (en) * 1988-12-29 1990-07-03 Sterling Drug Inc. 2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo(1,2,3-DE)-1,4-benzoxazines
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
DE69719765T2 (de) * 1996-08-27 2003-10-16 Wyeth, Madison 4-aminoethoxy-indolderivate als dopamin d2 agonisten und als 5ht1a liganden
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
FR2791344B1 (fr) * 1999-03-25 2002-02-15 Adir Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2793793B1 (fr) * 1999-05-19 2004-02-27 Adir Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI222450B (en) * 1999-07-28 2004-10-21 Upjohn Co Oxazinocarbazoles for the treatment of CNS diseases
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
JP2004526781A (ja) * 2001-04-20 2004-09-02 ワイス ５−ヒドロキシトリプトアミン−６リガンドとしてのヘテロシクリルアルコキシ−、−アルキルチオ−および−アルキルアミノベンザゾール誘導体

Also Published As

Publication number Publication date
NO20052730D0 (no) 2005-06-07
JP2006509777A (ja) 2006-03-23
NO20052730L (no) 2005-08-23
US20040132799A1 (en) 2004-07-08
TWI284124B (en) 2007-07-21
JP4339795B2 (ja) 2009-10-07
CN1713908B (zh) 2010-05-12
WO2004050085A1 (en) 2004-06-17
EP1569638B1 (en) 2007-09-05
BR0316962A (pt) 2005-10-25
ES2291722T3 (es) 2008-03-01
DE60316180D1 (de) 2007-10-18
CA2508315A1 (en) 2004-06-17
KR20050084155A (ko) 2005-08-26
EP1569638A1 (en) 2005-09-07
NZ539950A (en) 2007-05-31
AR042155A1 (es) 2005-06-08
ATE372113T1 (de) 2007-09-15
ZA200504412B (en) 2006-04-26
PL377464A1 (pl) 2006-02-06
HRP20050457A2 (en) 2005-10-31
MXPA05005790A (es) 2005-10-18
MY138466A (en) 2009-06-30
PA8589801A1 (es) 2004-11-26
RU2005121125A (ru) 2006-02-20
AU2003289903A1 (en) 2004-06-23
CN1713908A (zh) 2005-12-28
TW200413312A (en) 2004-08-01
KR100755580B1 (ko) 2007-09-06
DE60316180T2 (de) 2008-05-29
RU2350602C2 (ru) 2009-03-27
US7084169B2 (en) 2006-08-01
AU2003289903B2 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
PE20040763A1 (es) Derivados de aminoalcoxiindoles como ligandos de los receptores 5-ht6
PE20020720A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa
AR037222A1 (es) Un derivado de indol, su uso, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, y un procedimiento para preparar dicha composicion
AR066583A1 (es) Derivados de 3,3-espiroindolinona
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
BR0312758A (pt) Derivados de 1-heterociclilalquil-3-sulfonilazaindol ou -azaindazol como ligantes da 5-hidroxitriptamina-6
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
UY28150A1 (es) Agentes terapeuticos
AR049706A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
AR066111A1 (es) Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR030913A1 (es) Un compuesto derivado de indolina, su uso, un procedimiento para prepararlo, una composicion farmaceutica que lo comprende y un procedimiento para preparar dicha composicion
PE20130401A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos
PE20001543A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion en terapeutica
PE20091524A1 (es) Derivados de 2-aminopirimidina
PE20050726A1 (es) Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos
PE20020063A1 (es) Bis-arilsulfonas como ligandos del receptor de 5-ht
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
BRPI0412809A (pt) compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6
PE20090988A1 (es) Derivados de indol-2-ona como antagonistas del receptor de la grelina
PE20080941A1 (es) Compuestos triciclicos como agonistas del receptor de melatonina
AR055171A1 (es) Derivados de carboxamida como antagonistas del receptor muscarinico

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed